The purpose of this study is to learn about: * effects of living with COVID-19 and * how effective is nirmatrelvir-ritonavir in treating COVID-19. This is a study of two groups of COVID-19 patients in Taiwan. In Group 1 the below participants were included in the study: * Patients of all ages. * Patients who were confirmed to have COVID-19 infection between 01 January 2021 and 31 December 2021. * Cases of patients registered in the databases. In Group 2 the below participants were included in the study: * Participants who are 12 years or older. * Confirmed to have COVID-19 between 01 January 2022 and 31 December 2022. Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19. The study will look at: * the nature of Covid-19 disease. * as well as the experiences of people receiving the nirmatrelvir-ritonavir. This study will help to: * understand what type of patients will need to be admitted to hospitals. * see severe results due to COVID 19 infection. * have more knowledge on the use of nirmatrelvir/ritonavir on COVID-19.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Intensive Care Unit (ICU)
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required ICU
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require ICU
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a diagnosis of COVID-19 that did not require ICU
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a diagnosis of COVID-19 that required ICU
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome
Timeframe: 01 January 2021 to 31 December 2021
Cohort 2: Characteristics Associated with Patients Receiving nirmatrelvir/ritonavir vs Patients Not Receiving nirmatrelvir/ritonavir
Timeframe: 01 January 2022 to 31 December 2022